ABBV vs COP: Which Is the Better Buy?
Side-by-side comparison of AbbVie Inc. and ConocoPhillips — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-09-22.
AbbVie Inc. · Healthcare
$261.70
-1.0% upside to fair value
Med Conviction
Grade C
High Quality
VS
ConocoPhillips · Energy
$127.53
+32.1% upside to fair value
Med Conviction
Grade B
QuantHub Verdict
COP has more upside to fair value
(+32.1%).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
ABBV |
COP |
| Current Price |
$261.70 |
$127.53 |
| Fair Value Estimate |
$259.04 |
$168.50 |
| Upside to Fair Value |
-1.0%
|
+32.1%
|
| Market Cap |
$462.4B |
$155.4B |
| Forward P/E |
—
|
—
|
| EV / EBITDA |
24.8x
|
6.2x
|
| Price / Sales |
7.2x
|
2.5x
|
| Price / FCF |
23.6x
|
7.9x
|
| Revenue Growth YoY |
+10.2%
|
+36.8%
|
| Gross Margin |
71.5%
|
27.7%
|
| Operating Margin |
29.3%
|
21.9%
|
| Return on Equity |
-136.5%
|
14.3%
|
| Dividend Yield |
2.61% |
2.63% |
| FCF Yield |
4.25%
|
12.66%
|
| Analyst Consensus |
Strong Buy
|
Strong Buy
|
Investment Thesis
AbbVie is a diversified branded-biopharma company spanning immunology, neuroscience, oncology and aesthetics, with high-margin TTM economics including a 71.5% gross margin and 29.3% operating margin. Its successor immunology franchises are performing strongly: Q2 2026 revenue rose 10.2% year over year, with Skyrizi up 24.4% to $5.505 billion and Rinvoq up 24.5% to $2.525 billion, helping offset a…
ConocoPhillips is a global exploration and production company with a portfolio spanning unconventional North American shale, conventional international assets, LNG ventures, and Canadian oil sands, run by a new leadership team after Andy O'Brien became CEO on September 1, 2026. The business quality is medium: it generates substantial cash, with $16.15 in free cash flow per share and a 14.3% retur…
Accumulation Zones
| Metric |
ABBV |
COP |
| Zone Low |
$194.28 |
$126.38 |
| Zone High |
$220.18 |
$143.22 |
| In Buy Zone? |
No
|
Yes
|